DESIGN.md — Taiho Ventures

Per-style brand authority for src/styles/soft-futurism-ventures/. Produced and maintained by columbus-design-md-builder. Read by columbus-design-author at scaffold time and by columbus-design-iterator on every refinement. Treat sections 1–7 as canonical truth.

1. Aesthetic Anchor

Primary family: Glass / Soft-Futurism (Apple / Arc / Granola lineage — frosted depth, cool atmospheric layers, soft elevation on premium light surfaces) Secondary remix: Cult / Indie (A24 / Letterboxd / Aesop lineage — restrained, scientifically grave, takes itself seriously without irony or warmth-padding) Reference brands: Apple (atmospheric depth, premium light surfaces, frosted glass) × A24 (cult-indie typography, restrained image direction) × Aesop (apothecary restraint, laboratory glass tonality, scientific-but-human gravitas) Visual atmosphere: Cool, light, atmospheric — but not consumer. The page reads like a quiet research instrument: frosted card surfaces float above pale ambient gradients, typography is a precise variable serif paired with a tabular sans, and figures are tabular by default. Confidence comes from restraint and named specifics, not from mood adjectives. The Menlo Park venture team has its own visual identity; the Taiho parent corporate marks (Sepia, Red, Yellow) appear only in attribution lockups.

2. Brand Voice

Adjectives: clinical, patient, dry, exact, quietly confident Says:

"preclinical through proof of concept"
"we join syndicates we believe in"
"patient capital, by design"
named modalities and trial phases (e.g., "first-in-class small molecules", "IND to PoC", "Series A/B syndicates")
named co-investors when relevant (ARCH, GV, MPM Capital)
"Asia is a market, not a trophy" Avoids:
"we partner with bold founders"
"world-class" / "best-in-class" / "passionate" / "innovative" (alone)
"journey" / "ecosystem" / "transform" / "accelerate"
"Empower" / "unlock" / "elevate" / "leverage"
"Get started" / "Learn more" / "Sign up" — use first-person CTAs in the brand's voice
decorative em-dashes in copy (em-dashes are reserved for trial-phase markers and tabular separators) Sample sentences:

We back early-stage therapeutics in oncology, immunology, and urology — preclinical through proof of concept. We join syndicates led by ARCH, GV, and MPM. Our $400M is patient because Taiho is.

3. Color Palette & Roles

Mode: light primary, with selective dark hero moments (commit — not "supports both" as theme-toggle) Dominant: #F4F6F9 (--soft-futurism-ventures-paper) — pale cool stone page background, distinctly cooler than Apple's #FBFBFD, used for body and section surfaces Ink: #0E1525 (--soft-futurism-ventures-ink) — deep ink-blue body type and rules, never pure black Accent: #1F4D3B (--soft-futurism-ventures-pigment) — restrained spruce / laboratory-glass green, used sparingly for pull-quotes, single CTA chevron, masthead detail rules — never as a fill or large area Surfaces:

#FFFFFF at 65% opacity over paper (--soft-futurism-ventures-glass) — frosted card surface, used with backdrop-filter: blur(24px) saturate(140%)
#DDE2E9 (--soft-futurism-ventures-rule) — hairline borders, section dividers
#6B7280 (--soft-futurism-ventures-muted) — captions, marginalia, fund metadata
#0B1224 (--soft-futurism-ventures-deep) — dark hero surface for selective dark moments only Notes: Atmospheric soft cool gradients allowed in hero only (pale stone → ice-blue → near-white). Frosted glass surfaces with backdrop-blur are core. No saturated brand colors in the venture identity itself. Taiho parent corporate marks (Sepia #8A532C, Red #E31B13, Yellow #FABE00) appear only in attribution lockups and the Taiho parent footer credit, never as venture-site primaries.

4. Typography Rules

Headline font: Newsreader (Production Type) — https://fonts.google.com/specimen/Newsreader — variable, weights 200–700 used; mostly 400 with selective 200 (display-large) and 600 (callouts) Body font: Instrument Sans (Instrument) — https://fonts.google.com/specimen/Instrument+Sans — weights 400, 500, 600 Tabular font: JetBrains Mono — https://fonts.google.com/specimen/JetBrains+Mono — weights 400, 500 — used only for tabular figures (portfolio data, fund sizes, trial phases, dates), never body Pairing principle: High-contrast — variable editorial serif against geometric sans, with mono used surgically for tabular numerals and trial-phase markers Weight extremes: 200 (Newsreader display-large) vs 600 (Instrument Sans body bold). Avoid 500 in display contexts. Size scale: H1 4rem, H2 2rem, H3 1.25rem, body 1rem, caption 0.8125rem Max font sizes per page: 3 Banned (do not use): Inter, Roboto, Open Sans, Lato, system stacks, Space Grotesk, Manrope, DM Sans, Plus Jakarta Sans, Poppins, Montserrat, Nunito, IBM Plex Sans, Source Sans

5. Layout & Density

Grid: Asymmetric 12-col with frequent breaks. Hero uses full-bleed atmospheric layer with anchored 7-col content card and 5-col right-margin marginalia (fund metadata: $400M · est. 2016 · Menlo Park · Sand Hill Rd). Portfolio uses dense data-table treatment with sortable columns (therapeutic area, stage, modality, co-investors, outcome). Team is gridded 4-col but staggered — odd cards offset by 1 row. Case studies are wide editorial 8/4 with marginalia. Container max-width: 1280px Section rhythm: varied — quiet → dense → quiet → dense. Hero is atmospheric and quiet; mandate strip is single-line dense (rules above and below); portfolio is data-dense with sortable headers and tabular figures; case studies breathe wide; team grid is staggered. Density signals seriousness; whitespace signals confidence. Min container padding: 24px (mobile), 64px (desktop) Asymmetry / overlap commitments: Hero content left-anchored, right-margin marginalia for fund metadata. Mandate strip is centered (the only centered element on the page). Portfolio header rules break the grid intentionally — column dividers extend full-bleed beyond the 1280px container into the gutters. Pull-quotes in case studies hang into the right gutter in pigment color.

6. Backgrounds & Depth

Hero treatment: Atmospheric — a soft cool gradient (pale stone #F4F6F9 → ice-blue #E8EEF6 → near-white #FAFBFD) layered with a low-opacity (8%) architectural photograph as silhouette. Architectural means Japanese atelier interiors, laboratory glassware as form (pipettes, beakers, lab benches photographed for shape and light, not for content), or modernist clinic / research facility light studies. Never literal molecule renders, DNA helices, microscope close-ups, or stock biotech imagery. Optional dark hero variant uses #0B1224 with single point-light gradient and same architectural-silhouette overlay at 6% opacity. Atmospheric layers:

1px hairline rules between sections in --soft-futurism-ventures-rule
Subtle grain at 4% opacity over the hero gradient only (not full-page)
Frosted glass cards: backdrop-filter: blur(24px) saturate(140%) with --soft-futurism-ventures-glass background Shadow style: Subtle and atmospheric — large blur-radius, low-opacity, cool-tinted. Specifically 0 24px 48px -12px rgba(14, 21, 37, 0.08). Never harsh, never decorative, never warm.

7. Do's and Don'ts

Do:

Use frosted glass cards (backdrop-blur + low-opacity white) over atmospheric hero gradients — this is the brand signature
Set Newsreader at 4rem+ for editorial display headlines and let it carry the page; pair body at 1rem Instrument Sans
Write copy in named pharma-world specifics: preclinical, IND, PoC, modality, therapeutic area, named co-investors (ARCH, GV, MPM), real portfolio companies (Cullinan Pearl, Arcus, Orna, Harpoon)
Hang fund metadata and trial-phase markers in the right margin as marginalia in --soft-futurism-ventures-muted
Use the spruce-green pigment (#1F4D3B) sparingly — pull-quotes, single CTA chevron, masthead detail rules; if the page reads as "the green site," it has been overused
Use tabular figures (JetBrains Mono) for portfolio data, trial phases, fund sizes, and dates — visually distinct from body sans
Treat the audience as VC partners and PhD/MD associates first; founders second — copy density and tabular clinical detail signal credibility, then warmth comes through restraint, not adjectives

Don't:

Use Taiho Sepia (#8A532C), Taiho Red (#E31B13), or Taiho Yellow (#FABE00) as venture-site primaries — these are parent-corporate-mark colors, confined to logo lockups and parent attribution only
Use cream, paper, sepia, or warm-beige surfaces — those belong to sibling styles; the venture site is cool, not warm
Use Inter, Roboto, Manrope, Plus Jakarta Sans, Space Grotesk, Poppins, Montserrat, IBM Plex Sans, or any system stack
Use literal molecule renders, DNA double-helices, gloved hands holding pipettes, lab-coat people, or microscope close-ups — these are the AI-center for biotech sites
Use the 3-up icon-card "value props" feature grid — the AI-center for VC sites
Use centered hero with single CTA + sub-headline + 3-logo strip — the universal VC layout
Use purple gradients on white, blue→pink gradients, or any saturated AI-center hero gradient
Write CTAs like "Get started", "Learn more", "Sign up", "Discover more" — use first-person CTAs in the brand's voice ("Submit a pitch", "Read the mandate", "See the syndicates")
Use the words "world-class", "passionate", "journey", "ecosystem", "innovative" (without object), "transform", "unlock", "Empower" anywhere in copy
Use stock laboratory photography or generic biotech imagery libraries
Apply the spruce pigment as a fill, large area, or background — it's punctuation, not surface

8. Agent Prompt Guide

For any agent reading this file:

Read this DESIGN.md in full before writing any code, copy, or styling for soft-futurism-ventures.
Treat sections 1–7 as canonical truth. Don't override them inline.
Reject any change that violates the Don'ts in section 7. Surface the conflict to the user rather than silently picking one side.
If the user is asking for something this DESIGN.md doesn't cover, propose an addition to this file rather than introducing the decision in component code.
If the user is asking to change something in this file, route the request to columbus-design-md-builder rather than editing the file inline.
When sections conflict: section 7 (Don'ts) wins over everything; section 1 (Anchor) wins over sections 3–6; section 2 (Voice) is independent.
The audience-priority order matters: VC partners + PhD/MD associates first, founders second. When in doubt about copy density or technical specificity, lean institutional, not founder-friendly.

9. Notes & References

Created: 2026-04-28 Last updated: 2026-04-28 Source URL: n/a (real entity — research provided in research/: site brief, Taiho parent brand guidelines PDF, legacy site copy)

Reference brands fetched:

Apple — premium light surfaces, atmospheric gradients, frosted glass over ambient color, restrained typography
A24 — cult-indie typography sensibility, restrained image direction, takes itself seriously
Aesop — apothecary restraint, laboratory-glass tonality, scientific-but-human gravitas, surgical use of muted pigments
Taiho parent (research/Taiho-ventures-basic-branding-v0.pdf) — Communication Mark with Taiho Sepia (#8A532C), Taiho Red (#E31B13), Taiho Yellow (#FABE00); mandatory parent corporate identity preserved in attribution only

Category center notes (from competitor scan in site brief — Astellas Venture, Ono Venture, MRL Ventures, SR One, MPM BioImpact, GV Life Sciences, 5AM, Third Rock):

Most pharma-CVC sites: solid white background, blue + neutral gray accents, hero + portfolio logo grid, generic stock biotech imagery (microscopes, gloves, double-helix renders)
Voice converges on "transform / partner / accelerate / world-class / passionate"
Almost universal: 3-up value-prop strips, centered hero CTAs, simple logo grids without filtering or co-investor data
Almost no one uses tabular data treatments, scientific specifics, or atmospheric depth — the category default is flat and corporate
The differentiation lever is atmosphere + density + named specifics; this DESIGN.md is built to occupy that lane

Strategic positioning (from site brief):

Real entity: Taiho Ventures, LLC, founded 2016, Menlo Park (2420 Sand Hill Rd, Suite 203)
Parent: Taiho Pharmaceutical Co., Ltd. (Japanese specialty pharma; subsidiary of Otsuka Holdings)
Fund: $400M expanded, CVC dual mandate (financial returns + strategic relevance to parent)
Mandate: oncology, immunology, urology; preclinical → PoC; small molecules + biologics + gene/cell
Model: syndicate participant (not lead), build-to-buy, Asia commercialization gateway
Primary audience: VC partners + PhD/MD associates at top-tier life-science VCs (ARCH, GV, MPM)
Secondary audience: serial biotech entrepreneurs, academic founders
Core message: bridge between breakthrough science and global commercialization

External references:

Newsreader specimen: https://fonts.google.com/specimen/Newsreader
Instrument Sans specimen: https://fonts.google.com/specimen/Instrument+Sans
JetBrains Mono specimen: https://fonts.google.com/specimen/JetBrains+Mono
Site brief: research/TOI2601_TVL Site Brief_v3.docx
Taiho parent corporate identity: research/Taiho-ventures-basic-branding-v0.pdf
Legacy site copy: research/legacy-web-copy/

Additions log:

2026-04-28: Initial DESIGN.md captured by columbus-design-md-builder.

Landing

Open detail →

desktop 1440×900

soft-futurism-ventures.figmagic.local/landing

mobile 390×706

9:41

soft-futurism-ventures.figmagic.local